SDForum Quarterly Venture Breakfast with PWC
Pre-registration is now closed. Please register at the door.
In series four of the Venture Breakfast in collaboration with PWC, the panel will be discussing the biotech market. Biotechnology is the use of cellular and biomolecular processes to solve problems or make useful products.
There are more than 370 drug products and vaccines currently in clinical trials targeting more than 200 diseases. Hundreds of biopesticides and other agricultural products also are being used to improve our food supply and to reduce our dependence on conventional chemical pesticides. Biotechnology is a fascinating and changing market, but what does it take to survive and succeed?
- Moderator: Allison Leopold Tilley, Pillsbury Winthrop
- Steve Bengston from PWC
- Lou Bock, Scale Venture Partners
- David Lowe,PhD, Skyline Ventures
- Evgeny Zaytsev, Asset Management Company
About the Speakers:
Steve Bengston from PWC, runs the Emerging Company Services (ECS) group at PricewaterhouseCoopers. ECS helps companies informally with referrals to investors and other people that can help startups and more formally with services like audit and tax. Steve also presents the Money Tree data each quarter which summarizes venture capital investment results and trends.
Lou Bock, Scale Venture Partners is an industry veteran and is focused on identifying emerging biopharmaceutical, device and platform technology companies. Lou sits on the Boards of Ascenta Therapeutics, diaDexus, Horizon Therapeutics, Orexigen Therapeutics, SGX Pharmaceuticals and Zogenix.
Lou joined Scale Venture Partners in 1997 from Gilead Sciences, where he held positions in research, project management, business development and sales. While at Gilead, Lou was the project manager for Gilead's approved antiviral drug, Vistide, and was responsible for the discovery of Gilead's novel thrombin aptamer. Previous to Gilead, he was a research associate at Genentech.
Allison Leopold Tilley, Pillsbury Winthrop, Allison Leopold Tilley, a partner at Pillsbury Winthrop, focuses on the representation of technology companies in securities and venture capital transactions, including mergers and acquisitions, private placements, public offerings, venture funds and joint ventures. She has significant experience representing acquirers and target companies. Ms. Leopold Tilley is co-head of the Firm’s Information Technology Practice Team, Head of the Silicon Valley Business and Technology Group and co-head of the Southeast Asia Specialty Team.
David Lowe, PhD is a Managing Director and joined Skyline Ventures in 2002. Currently he serves on the board of directors for the privately held companies Applied Genetic Technologies Corporation (AGTC), Proteon Therapeutics, ARCA Discovery, and Sequel Pharmaceuticals, and previously served on the board of directors of Avidia (acquired by Amgen), NimbleGen Systems (acquired by Roche), and NovaCardia (acquired by Merck). Prior to joining Skyline he was at Genentech for 16 years as a scientist and Director of Cardiovascular Research. At Genentech, David led drug discovery activities in biologics and small molecule therapeutics and was responsible for the discovery efforts resulting in eight drug candidates taken into clinical development. He was a member of the therapeutic area team responsible for cardiovascular strategic planning and product portfolio management, and worked extensively with Business Development on in-licensing of early and late-stage therapeutics, and technology access. David holds a Ph.D. in biochemistry from the University of Toronto, Canada, and has published more than 60 articles in scientific journals.
Dr. Evgeny Zaytsev, Asset Management Company she joined Asset Management Company in 2001 bringing diverse professional experience in operations and biomedical research.
$20 for SDForum members
$30 for non-SDForum members
No Charge for SDForum Platinum Pass Members
Pillsbury Winthrop Shaw Pittman LLP
2475 Hanover Street
Palo Alto, CA 94304